This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Women with polycystic ovarian syndrome (PCOS) generally are treated with oral contraceptives, "fertility drugs" to induce ovulation, or—when all else fails—surgical wedge resection. But tentative clinical impressions now suggest that dopamine agonists used to treat hyperprolactinemia may become a therapeutic option for these patients. (For discussion of another use of dopamine agonist therapy, see "Galactorrhea Without Hyperprolactinemia" on page 593.)
At the recent Endocrine Society meeting in San Francisco, Jon J. Pehrson, MD, a fellow in endocrinology and metabolism at Boston City Hospital, reported that the disease may entail alterations in dopaminergic control of prolactin secretion. Pehrson and Judith L. Vaitukaitis, MD, of Boston University School of Medicine, who is chief of endocrinology at the city hospital, found slightly elevated basal serum prolactin levels in about one third of 42 affected women (none of whom had pituitary tumors or congenital adrenal hyperplasia) during protracted amenorrhea or the early follicular phase
González ER. Dopamine agonists for polycystic ovary disease? JAMA. 1982;248(5):514. doi:10.1001/jama.1982.03330050004002
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: